Please login to the form below

Not currently logged in
Email:
Password:

Boost belies Lilly's concerns

Eli Lilly & Co has reported an impressive 84 per cent increase in first quarter earnings, although question marks remain after slowing sales.

Eli Lilly & Co has reported an impressive 84 per cent increase in first quarter earnings, although question marks remain after slowing sales of two key drugs.

The Indianapolis-based company, without any significant patent expiry in the near future, increased net income to $736.6m, or 68 cents a share from $400.4m a year earlier. First quarter sales rose 4 per cent to $3.5bn.

Despite its robust performance, Lilly cautioned that sales would decline for the full year. It also forecast that attention deficit disorder (ADHD) drug, Strattera, mainly prescribed to hyperactive children in the US, would experience slower prescription growth due to parents' worries over its safety.

Lilly recently added a warning to Strattera's label, advising patients with liver problems to stop taking the drug.

Meanwhile, sales of schizophrenia blockbuster, Zyprexa, fell 5 per cent to $1.04bn in the quarter after it encountered stiff competition from Bristol-Myers Squibb's rival treatment, Abilify. Although international sales of Zyprexa grew, analysts said the growth was less than they had predicted.

Lilly remained bullish, saying that sales of newer medicines such as antidepressant Cymbalta, cancer drug Alimta, and the male-impotence pill Cialis, compensated for the Zyprexa decline. Chief executive, Sidney Taurel, said eight of the company's newest products would generate 20 per cent of sales this year.

ìThey are heading in the right direction, but so far their execution is inconsistent,î commented Les Funtleyder, healthcare strategist at Miller Tabak & Co.

Another factor that put a dent in first quarter sales was Lilly's restructuring of its distribution contracts with wholesalers. The new contracts have caused the wholesalers to reduce inventory levels of Lilly drugs, shaving $130m off first quarter sales, said the company.

Morgan Stanley analyst, Jami Rubin, wrote in a research note that the $120m in first-quarter Strattera sales fell well short of the analyst's estimate of $170m.

ìWe believe these arrangements provide us with competitive distribution costs and reduced speculative buying by wholesalers,î said James Ward, executive director of Lilly's investor relations.

More encouraging news for Lilly in the last week has been a US District Court's ruling to uphold the 2011 patent on Zyprexa after generic firm Zenith Goldline challenged it.

30th September 2008

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics